How should a 70‑year‑old man with a prior myocardial infarction on antiplatelet therapy be managed after a recurrent stroke?

Management of Recurrent Stroke in a 70-Year-Old Male with Prior MI on Antiplatelet Therapy

For this 70-year-old man who developed a recurrent stroke while on antiplatelet therapy, you should immediately investigate the stroke mechanism and consider switching or intensifying antiplatelet therapy based on stroke severity and timing, while carefully weighing bleeding risks given his age.

Immediate Assessment and Stroke Characterization

First, determine the stroke mechanism through appropriate diagnostic workup, as this fundamentally guides treatment decisions 1:

• Complete vascular imaging (carotid and intracranial vessels) to identify large vessel atherosclerosis or stenosis 1
• Cardiac rhythm monitoring to exclude atrial fibrillation or other cardioembolic sources 1
• Assess stroke severity using NIHSS score, as this determines eligibility for dual antiplatelet therapy 1
• Timing from symptom onset is critical, as treatment windows differ for various interventions 1

The stroke mechanism matters because cardioembolic strokes require anticoagulation rather than antiplatelet therapy 1.

Acute Management Based on Stroke Severity

For Minor Stroke (NIHSS ≤3) or High-Risk TIA

If presenting within 72 hours of symptom onset and the stroke is non-cardioembolic, initiate dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel 2:

• Clopidogrel 300 mg loading dose, then 75 mg daily 2
• Aspirin 100-300 mg loading dose, then 100 mg daily 2
• Continue DAPT for 21-90 days, then transition to single antiplatelet therapy (SAPT) 1

The INSPIRES trial (2023) demonstrated that DAPT initiated within 72 hours reduced new stroke risk (7.3% vs 9.2%, HR 0.79, P=0.008) compared to aspirin alone, though with increased moderate-to-severe bleeding (0.9% vs 0.4%) 2. The benefit is most pronounced when started within 12-24 hours but extends to 72 hours 1, 2.

For Minor to Moderate Stroke (NIHSS ≤5) Within 24 Hours

Consider ticagrelor plus aspirin for 30 days as an alternative, though this carries higher bleeding risk 1:

• Ticagrelor 180 mg loading dose, then 90 mg twice daily 1
• Aspirin 300-325 mg loading dose, then 75-100 mg daily 1
• Duration: 30 days only 1

The THALES trial showed modest benefit (5% vs 6.3% recurrent stroke, NNT=92) but significantly increased severe bleeding (0.5% vs 0.1%, NNH=263) and intracranial hemorrhage (0.4% vs 0.1%) 1. Given this patient's age of 70 years, the bleeding risk is particularly concerning, as older patients have higher ICH risk with DAPT 1.

Long-Term Secondary Prevention Strategy

Switching vs. Continuing Antiplatelet Therapy

The evidence for switching antiplatelet agents in patients already on therapy who experience recurrent stroke is limited but suggests potential benefit 1:

• A meta-analysis showed reduced recurrent stroke risk (HR 0.70) when switching from one antiplatelet to another or adding DAPT 1
• A prospective registry found maintaining aspirin alone had higher recurrent stroke rates (8.0%) compared to switching (6.9%) or adding another antiplatelet (6.6%) 1
• However, a 2017 observational study found no significant difference in 90-day outcomes between switching and continuing the same regimen 3

After completing the acute DAPT course (21-90 days), transition to long-term SAPT 1:

• Clopidogrel 75 mg daily is preferred if the patient was previously on aspirin 1
• Aspirin 50-325 mg daily (consider weight-based dosing: 75-100 mg if <70 kg, higher doses if >70 kg) 1
• Aspirin 25 mg plus extended-release dipyridamole 200 mg twice daily as an alternative 1

Critical Caveat: Avoid Prolonged DAPT

Do not continue DAPT beyond 90 days, as this significantly increases hemorrhage risk without additional stroke prevention benefit 1:

• Long-term DAPT (aspirin plus clopidogrel) shows no benefit over SAPT for recurrent stroke prevention 1
• Bleeding risk begins outweighing benefit as early as 21-90 days 1
• This 70-year-old patient is at particularly high risk for ICH with prolonged DAPT 1

Special Consideration: Prior MI and Dual Vascular Disease

This patient's history of prior MI creates a complex scenario, as he has both cerebrovascular and coronary disease 4, 5:

• The CHARISMA trial subgroup analysis showed patients with prior MI, stroke, or PAD benefited from long-term DAPT (clopidogrel plus aspirin) with reduced cardiovascular death, MI, or stroke (7.3% vs 8.8%, HR 0.83, P=0.01) 4
• A meta-analysis of patients with prior MI showed extended DAPT reduced cardiovascular death (RR 0.85) and MI (RR 0.70) but increased major bleeding (RR 1.73) 5

However, for stroke prevention specifically, the stroke guidelines take precedence: limit DAPT to 21-90 days post-stroke, then transition to SAPT 1. If there are other compelling cardiac indications for prolonged DAPT (e.g., recent drug-eluting stent within the past year), this should be explicitly documented and time-limited 1.

Risk Factor Optimization

Beyond antiplatelet therapy, aggressively manage modifiable risk factors 1:

• High-intensity statin therapy (atorvastatin or rosuvastatin) to reduce LDL-C by ≥50% and achieve LDL-C <70 mg/dL 1
• Blood pressure control to target (generally <130/80 mmHg for most stroke patients) 1
• Smoking cessation if applicable 1
• Diabetes management if present 1

Monitoring and Follow-Up

• Assess for bleeding complications during DAPT, particularly in this older patient 1
• Ensure transition from DAPT to SAPT occurs at 21-90 days to avoid prolonged bleeding risk 1
• Monitor for medication adherence, as recurrent events often relate to poor risk factor control 1
• Consider CYP2C19 genetic testing if clopidogrel resistance is suspected, though routine testing is not currently recommended 6, 7